Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

Welcome to Zymeworks first-quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...